Episode 125: The Power of Botanicals in Skin Care | The Future of Dermatology Podcast

About this episode

Dr. Faranak Kamangar and Dr. Peter Lio discuss advancements in dermatology, including botanicals in skin treatment and the gut-skin connection.

Summary In this episode of the Future of Dermatology podcast, Dr. Faranak Kamangar and Dr. Peter Lio discuss significant advancements in dermatology, including the recent approval of an ICD 10 code for topical steroid withdrawal, the exploration of botanicals in skin treatment, and the emerging understanding of the gut-skin connection. They also delve into the role of GLP medications in managing skin conditions and the exciting future developments in dermatology, particularly in the treatment of atopic dermatitis. Read the referenced documents at the following sites:- Ancient botanicals and the skin: Defining dermatologic ethnophytoconvergence as a translational framework for pharmacognosy: https://doi.org/10.1016/j.jdrv.2025.12.008- The Gut-Skin Axis: Exploring the Role of SCFAs, Obesity, and GLP-1 Receptor Agonists in Atopic Dermatitis: https://jintegrativederm.org/article/view/109- Topical Steroid Withdrawal is a Targetable Excess of Mitochondrial NAD+: https://www.medrxiv.org/content/10.1101/2024.04.17.24305846v1.full-text- Jennifer Fugo information: https://www.skinterrupt.com/book-a-session/ Takeaways - The CDC has approved an ICD 10 code for topical steroid withdrawal…

People in this episode

Guests: Dr. Faranak Kamangar, Dr. Peter Lio

Topics covered

• botanicals in skin care
• topical steroid withdrawal
• gut-skin connection
• GLP medications
• atopic dermatitis

Keywords

• dermatology
• botanicals
• topical steroid withdrawal
• atopic dermatitis
• GLP medications
• gut-skin connection

Mentioned in this episode

Organizations: CDC, Jennifer Fugo

Books & works: Ancient botanicals and the skin: Defining dermatologic ethnophytoconvergence as a translational framework for pharmacognosy, The Gut-Skin Axis: Exploring the Role of SCFAs, Obesity, and GLP-1 Receptor Agonists in Atopic Dermatitis, Topical Steroid Withdrawal is a Targetable Excess of Mitochondrial NAD+

More episodes of The Future of Dermatology

• Episode 133: HS Treatment Pipeline Explosion: What's New & What's Next | The Future of Dermatology Podcast · June 2, 2026 · 23 min
• Episode 132: Behind the Scenes: Podcast Milestones, SF Derm 2026, & Derm GPT | The Future of Dermatology Podcast · May 19, 2026 · 25 min
• Episode 131: HS Updates, Prior Auth Reform & CA Legislation in Dermatology ft. Dr. Haley Naik | The Future of Dermatology Podcast · May 5, 2026 · 27 min
• Episode 130: Agentic AI Workflows Explained | The Future of Dermatology Podcast · April 7, 2026 · 22 min
• Episode 129: AI Pearls for Dermatologists: What Every Derm Needs to Know in 2026 | The Future of Dermatology Podcast · March 31, 2026 · 21 min
• Episode 128: The AI Takeover Is Already Happening, And Maybe That's Okay | The Future of Dermatology Podcast · March 17, 2026 · 46 min